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Patient safety in intensive care
medicine
Improving the outcome of critically
ill patients remains an ideal that every
practicing Intensivist strives to
achieve. Every year there are many
hundreds of research papers
published that help us to better
understand the physiology and path-
ophysiology of our patients and also
how our treatment strategies interact
and eventually alter a patient’s
course. Many of these papers focus on
discrete parts of the therapeutic
regimes that we are able to deliver;
however, few have had a signiﬁcant
impact on overall outcome measures
that are relevant to patients them-
selves. One area of medicine that is
often overlooked, but can impact
signiﬁcantly on relevant patient
outcomes, is the process of care. The
way we practice, the culture we work
in, the climate that our professional
demeanor creates can all dramatically
impact on outcome measures. Unfor-
tunately, these topics are often not
easy to explain, difﬁcult to study and
do not attract research funding that
stimulates scientiﬁc minds to address
the problem. This paper describes
how the European Society of Inten-
sive Care Medicine (ESICM) aims to
raise patient safety to the top of the
scientiﬁc agenda with the hope of
ultimately increasing the quality of
care delivered to our patients and
improving their outcomes.
The Institute of Medicine (IOM)
published in 1999 their seminal report
entitled ‘To err is human: building a
safer health system’ [1]. This paper
described quality as the degree to
which health services for individuals
and populations increase the likeli-
hood of desired health outcomes and
are consistent with current profes-
sional knowledge. Safety was deﬁned
as the absence of clinical error, either
by commission (unintentionally doing
the wrong thing) or omission (unin-
tentionally not doing the right thing)
[2], and error as the failure of a
planned action to be completed as
intended or the use of a wrong plan to
achieve an aim. The accumulation of
errors results in accidents. The
authors delineated just how common
failure to provide quality care is, with
between 44,000 and 98,000 patients
dying each year in the USA as a result
of a clinical error. This makes medi-
cal error the eighth leading cause of
death, more frequent than motor
vehicle accidents (43,458), breast
cancer (42,458) and AIDS (16,516).
Despite the awareness of patient
safety and quality of care issues
increasing in both patient and politi-
cal arenas, this has not translated
through to groundbreaking research
studies that have ignited the
topic with signiﬁcant outcome
beneﬁts [3, 4].
To improve the proﬁle of these
subjects, the ESICM in 2009 has
launched a major initiative that will
bring together the representatives of
Critical Care Societies from around
the world (national and international)
with the aim of pledging their efforts
and resources towards improving the
care of our patients. Together with the
societies signing this Declaration of
Vienna (Appendix 1) will be senior
representatives from the political
world, our partners in industry and of
course patient representatives them-
selves. The meeting will assess
problems and solutions from around
the world irrespective of geographi-
cal, political or economic factors.
This unique partnership will allow
collaborations to be fostered and for
partnerships to develop. We hope to
be able to use this group to raise the
proﬁle of the patient safety agenda
and therefore change the way we
practice everyday with resultant ben-
eﬁts for all.
From efﬁcacy to effectiveness
Patient safety in intensive care med-
icine is best evaluated in terms of two
dimensions:
• at the individual patient level, by
doing good and not doing harm to
any individual patient;
• at the collective level by doing
good and not doing harm to groups
of patients, by increasing the safety
and the effectiveness of our inter-
ventions or in other words, the
cost–beneﬁt ratio.
Although at the level of the indi-
vidual patient there is little difﬁculty
in explaining what is meant by the
concept of safe practice, at a collec-
tive level this is far more complex.
Partly this is because often the con-
cepts are more easily addressed by
complex statistical approaches when
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the fact that they relate to the two
pillars of quality, efﬁcacy and effec-
tiveness [5]. This difference
between efﬁcacy and effectiveness
is very important to understand [6].
Efﬁcacy relates to the capacity of an
intervention to produce an effect,
for instance in a research trial,
effectiveness relates to how well
this translates to improved outcomes
in real-life pragmatic situations. The
standards for the evaluation and
reporting of the efﬁcacy of an inter-
vention are now reasonably well
established, despite several concerns
surrounding methodological pitfalls
[7]. These standards have been
described both for the individual
level situation [8] and also where
the evidence is arising from a vari-
ety of different sources [9]. When
we move from efﬁcacy to effective-
ness, the picture is not so clear.
These problems are usually seen
when trying to translate research
scenarios into everyday clinical
practice, or when trying to develop
or assess clinical practice recom-
mendations or guidelines. The
deﬁnitive answer about the risk-ben-
eﬁt balance of any intervention can
only be made when the balance
between the expected beneﬁts and
the expected risks is assessed in the
real world, outside of the experi-
mental setting. To move from what is
known about the beneﬁts, the risks
and the limitations of a certain
intervention when applied in a very
strict usually non-generalizable
cohort of patients to everyday prac-
tice is very difﬁcult. This often relates
to patient case mix differences,
severity of illness differences and the
effects of multiple interventions
impacting on each other that were not
fully assessed in the original trial.
If we take clinical practice guidelines,
there are many examples of recom-
mendations that have been
suggested following single trials
that have been subsequently refuted
when more data became available
[10, 11]. For these reasons, and due
to an innate bias between the
appraisal of evidence and clinicians
own past experience and beliefs [12],
orthodox medicine is often not evi-
dence based [13], and anecdote is
often used as to determine treatment
plans [14].
Why now: the changing
demographics of intensive care
medicine?
Recent years have witnessed great
changes in the topology of the human
population. We are now greater in
number and older in age. We are
sicker and more dependent on pro-
phylactic and preventive therapies.
Resources are becoming scarcer and
are increasingly becoming more
unevenly distributed. Diseases are
becoming more global. Technological
advancements have allowed, and
been the stimulus for, the develop-
ment of our specialty, intensive care
medicine. This specialty cares for and
treats patients with acute life-threat-
ening illnesses. The prevention, care
and/or cure of these patients are now
a global challenge, needing multiple
local solutions.
Contrary to previous times,
where almost all of the health chal-
lenges could be addressed by single
interventions, such as vaccines,
antibiotics or nutritional supple-
ments, or eventually by small
packages of interventions (washing
of hands before interventional
childbirth, surgery with anesthesia,
prophylactic antibiotics before sur-
gery), critical illness is unique in
several respects:
• in its dimensions: it is a situation in
which every organ and many of the
inter-related systems may be
affected, either as a primary or
secondary phenomena;
• in its time-dependence: most of the
diagnostic and therapeutic inter-
ventions must be performed
exceptionally quickly in order to be
given a chance to work;
• in its challenges: the acceptability
of the practice of intensive care
medicine is crucially dependent on
the application of the strictest eth-
ical standards. These have to be
maintained with the utmost respect
for the patient (and their family’s)
wishes and in accordance with
society’s values and expectations.
These may change with time and
certainly change with cultural,
religious and geographic
demographics;
• in its consequences: the increasing
prevalence of residual disability
post-critical illness, with the con-
sequent burden on the patient, their
families and on society as a whole,
has an impact for many years after
the acute illness.
The current pandemic of critical
illness will spare few and will be part
of the dying process of millions of
human beings in the forthcoming
decades, with an increasing number
of patients requiring intensive care as
part of their therapeutic plans or end
of life care. Given the narrow thera-
peutic margins for a signiﬁcant
number of the interventions belong-
ing to our ﬁeld, it is probable that a
signiﬁcant number of patients will be
injured and will suffer from the
unattended consequences of medical
practice. An important dimension of
this problem, which can either be
caused by errors of action or by errors
of omission in the process of care
delivery, are the educational and
training standards of all professionals
involved. We have to recognize that
the safety of our patient’s and also our
health-care teams is of the utmost
importance. However, despite recent
reports on the increasing disparity
between the supply and demand of
intensive care [15] and on the proven
effectiveness of the intervention of
intensive care specialists on patient
care, both physicians [16, 17] and
nurses [18], this problem remains
hidden and unaddressed by planners
of health-care systems and those
responsible for the planning of
medical education. Consequently, we
1668can expect to see an increase in the
impact of these phenomena.
Error in intensive care
Two recent studies performed by
the Health Services Research and
Outcomes Section of the ESICM
have helped to bring light to this
issue. In the ﬁrst study, the sentinel
events evaluation (SEE) study,
Valentin [19] performed an observa-
tional, 24-h cross-sectional study of
incidents in 205 intensive care units
around the world. Thirty-nine seri-
ous events were observed for
every 100 patient days. The events
included medication errors (136
patients), unplanned dislodgement or
inappropriate disconnection of lines,
catheters and drains (158), equip-
ment failure (112), loss, obstruction
or leakage of artiﬁcial airway (47)
and inappropriate turning-off of
alarms (17). The presence of organ
failure, a higher intensity in level of
care and time of exposure all related
to these events. In 2009, the same
group, focusing this time on errors in
the administration of parenteral
drugs, found 74.5 events per 100
patient days in the SEE 2 study [20].
Interestingly, three quarters of the
errors were classiﬁed as errors of
omission; 1% of the study popula-
tion experienced permanent harm or
died because of a medication error at
the administration stage. The odds
ratios for the occurrence of at least
one parenteral medication error were
raised depending on the number of
organ failures, the use of any intra-
venous medication, the number of
parenteral administrations, typical
interventions in patients in intensive
care, a larger intensive care unit,
number of patients per nurse and
unit occupancy rate. Odds ratios for
the occurrence of parenteral medica-
tion errors were decreased for the
presence of basic monitoring, an
existing critical incident reporting
system, an established routine of
checks at nurses’ shift change and an
increased ratio of patient turnover to
the size of the unit.
Although these above examples
all relate to individual patients, a
bigger and less reported problem is
that of the omission or commission of
therapies for populations of patients.
In intensive care practice this may
relate to the provision of appropri-
ately sized tidal volumes during
mechanical ventilation or the timely
use of antimicrobial therapy in septic
shock [21, 22]. In other clinical situ-
ations, it may relate to the patients
being discharged post-acute myocar-
dial infarction being prescribed
appropriate doses of beta-blocker and
statin therapies.
What are the causes of an unsafe
ICU and how can we improve the
safety culture and environment
within our intensive care units?
Deﬁning and assessing safety and
quality are only one side of the issue.
Often in clinical practice the problem
is broader than individual errors, and
the whole system is at fault or at the
least predisposes to an unsafe envi-
ronment. When assessing an ‘unsafe’
ICU, several factors need to be
understood,andtheseﬁtintotwomain
categories: problems with the organi-
zation and structure of the unit and
problemswiththeprocessofcareused.
Perhaps the most obvious factors
from the organization or structural
point of view relate to the volume of
work performed and outcome. This
topic remains contentious [23],
although there is good evidence to
support centralization and increased
volume services in many circum-
stances [24, 25] (Nathens, 2001 no.
10382). Some authors have described
the relationship between patient to
nurse ratios and nosocomial infection
rates [26], medication errors [20],
complications and resource use after
esophagectomy [18] or more broadly
even all the aspects of safety and
quality in the hospital [27]. These
works lead many authors to conclude
that a high-acuity nurse-patient ratio
is cost-effective [28], and that it is
crucial to have ICUs adequately
staffed [29].
The process of care relates to
issues of teamwork, collaboration and
communication. These issues are far
more difﬁcult to quantify and are
often obscure and forgotten. In
intensive care medicine they were
perhaps ﬁrst raised by Pascale le
Blanc and Wilmar Schaufeli in the
EURICUS studies [30, 31]. They
demonstrated these variables to be
associated with increasng nosocomial
infection rates [32]. Among these
aspects, the issue of nurse–physician
collaboration in ICUs [33–35] seems
to be crucial. Also, the issue of the
transmission of individual informa-
tion between professionals is today a
critical issue [36], ﬁrst raised by
Donchin in 1995 [37] and later con-
ﬁrmed in the SEE study [19]. Not
withstanding these issues, it is
important not to forget the well-being
of intensive care nurses [38] or the
effect of a pharmacist’s and/or a
nurse’s interventions on cost and
adverse effects of drug therapy in the
ICU [39–41].
The need for a multidimensional
approach to the minimization of error
and the consequent improvement in
the clinical and economical effec-
tiveness of an ICU is becoming
increasingly clear [42]. When com-
paring the ‘‘most efﬁcient’’ with
‘‘least efﬁcient’’ ICUs, Rothen and
co-workers demonstrated that only
interprofessional rounds, the presence
of an emergency department and the
geographical region of the hospital
were signiﬁcantly associated with
improvement in quality indicators.
The adoption of electronic prescrib-
ing over handwritten prescription has
also been shown to lead to the pre-
scriptions being more readable and
complete, with fewer errors. This
should result in improved prescribing
and a safer environment for the giving
of drugs to our patients.
1669In conclusion, a signiﬁcant num-
ber of dangerous human errors occur
in the ICU. Many of these errors can
be attributed to problems of commu-
nication between the physicians and
nurses. Applying human factor engi-
neering concepts to the study of the
weak points of a speciﬁc ICU may
help to reduce the number of errors.
Errors should not be considered as an
incurable disease, but rather as pre-
ventable phenomena, if systems were
designed to cope and to minimize the
effects and the consequences of these
errors [43].
The challenges for the future
Medicine in the last 200 years has
changed dramatically. The nature of
health and disease has altered irrevo-
cably, pain has been conquered with
anesthesia, and infectious diseases
have been fought through a combi-
nation of drugs and better public
health systems. At the same time our
understanding of the pathophysiolog-
ical process underpinning these
changes has improved exponentially.
Despite these advancements, our
knowledge as to how health-care
systems interact and inﬂuence the
delivery of safe and quality care are
poor. The recent ‘‘discovery’’ of the
epidemic of ‘‘medical error’’ as an
important cause of morbidity and
mortality should not be a surprise.
The ﬁrst step to overcome this pre-
ventable epidemic is by the
recognition of its existence. For this
reason the ESICM is promoting an
initiative to bring together all the
stakeholders who relate to our spe-
cialty in a process aimed at not only
raising the proﬁle of patient safety,
but to actually improve the outcome
of our patients.
Appendix 1
1. We, the Leaders of the Societies
representing the medical specialty
of intensive care medicine, met in
Vienna on 11 October 2009.
Together with the representatives
of the main institutions and
stakeholders who speak up for
patient safety, we declare:
2. We recognize that patient safety
and clinical team safety are of
paramount importance to every
practicing health professional and
represents one of the major chal-
lenges in modern day medicine.
This affects the lives of women,
men, and children in every coun-
try. Without a safe environment it
is not possible to provide the
quality of care that we all aspire
to. This is especially true in
intensive care medicine, given the
very fragile nature of the patients
we care for, often in the extremes
of age, unconscious and with
minimal margins for error imposed
by their deranged physiology. This
global problem requires a global
solution.
3. We believe that improving levels
of safety for critically ill patients is
achievable in all units and in all
countries, irrespective of the
available resources. If the safety of
our patients is increased, then the
quality of care that we can provide
will improve.
4. We strongly believe that increas-
ing patient safety is as crucial to
the development of medical prac-
tice as the increase in the
effectiveness of our interventions.
5. We have today therefore pledged
to do whatever is necessary to:
• Increase the knowledge of the
causes and reasons for failures
to provide a safe environment in
the intensive care unit.
• Improve our understanding of
the consequences of failure to
provide a safe environment for
critically ill adult and children
and the health-care profession-
als caring for these patients.
• Develop and promote criteria
that can assess safety in the
intensive care unit.
• Further our ability to translate
the knowledge of safety into
improving the quality of care
that can be provided to our
patients.
By acting together to fulﬁll these
pledges we will improve the safety of
intensive care practice and thereby
increase the quality of care.
6. Through the design and promotion
of safer and even more efﬁcient
devices and drugs, we acknowl-
edge that industrial partners have a
pivotal role to play in improving
patient safety. With the signature
of this declaration, manufacturers
of biomedical, pharmaceutical and
biotechnology companies pledge
to:
• Engage in efforts to improve the
safety proﬁle of their products.
• Provide resources to facilitate
the safe use of their products.
• Release, as soon as they become
available, any information
related to safety concerns of
their products to health-care
professionals and regulatory
agencies.
7. The agreements reached today will
enable us to develop safety criteria
that can be used by intensive care
units around the world to improve
their safe practices and increase
the quality of care provided to the
beneﬁt of all of our patients.
Appendix 2
Critical care societies who are
participating in the initiative
Associac ¸a ˜o de Medicina Intensiva
Brasileira (AMIB)
Asia-Paciﬁc Association of Criti-
cal Care Medicine
Australian and New Zealand
Intensive Care Society
Austrian Society of Medical and
General Intensive Care Medicine
Bahrain
1670Belgian Society of Intensive Care
Medicine
Canadian Critical Care Society
Chinese Society of Critical Care
Medicine
Croatian Society of Intensive Care
Medicine
Czech Society of Intensive Care
Medicine
Deutsche Gesellschaft fur Anas-
thesiologie und Intensivmedizin
Deutsche Interdisziplinare Veren-
igung fur Intensiv- und
Notfallmedizin
EBA President
Egyptian Society of Critical Care
and Emergency Medicine
Emirates Intensive Care Society
ESPNIC
Estonian Society of
Anaesthesiologists
European Federation of Critical
Care Nursing Associations
European Society of
Anaesthesiologists
Finnish Society of Intensive Care
Georgian Society of Anesthesiol-
ogy and Critical Care Medicine
German Sepsis Society
Hungarian Society of Anaesthesiolo-
gy and Intensive Care Therapy
Indian Society of Critical Care
Medicine
Indonesian Society of Intensive
Care Medicine
Intensive Care Society
International Pan-Arab Society of
Intensive Care Medicine
Israel Society of Critical Care
Medicine
Korean Society of Critical Care
Medicine
Kuwait
Lithuanian Society of Anaesthe-
siology and Intensive Care
Macedonia Society of Anaesthesia
and Intensive Care
Malaysian Society of
Anaesthetists
Nederlandse Verenigning voor
Intensive Care
Osterreichische Gesellschaft fur
Anaesthesiologie, Reanimation und
Intensivmedizin
Romanian Society of Anaesthesia
and Intensive Care
Scandinavian Society of Anaes-
thesiology and Intensive Care
Scottish Intensive Care Society
Serbian Society of Intensive Care
Medicine
Slovak Society of Anaesthesiolo-
gy and Intensive Care
Sociedad Espanola de Anestesio-
logia, Reanimacion y Terapeutica del
Dolor
Sociedade Portuguesa de Cuida-
dos Intensivos
Sociedad Espan ˜ola de Medicina
Intensiva, Crı ´tica y Unidades
Coronarias
Societa ` Italiana Di Anestesia
Analgesia Rianimazione E Terapia
Intensiva
Socie `te ` de Re `animation de Lan-
gue Franc ¸aise
Socie `te ` Francaise d’Anesthe `sie et
de Re `animation
Society of Anaesthesiologists and
Reanimatologists of Central Russia
Society of Critical Care Medicine
Sudan
Swedish Society of Anaesthesiol-
ogy and Intensive Care Medicine
Swiss Society of Intensive Care
Medicine
Tunisia
UEMS
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